Evidence map›Paper›PMID 40533758›Full record

ArticleJournal of nanobiotechnology2025

Human serum albumin-based KBiF

Yuelin Huang, Zhenghai Lu, Huanhuan Liu, Ningxin Yang, Yanhong Chen, Chunting Wang, Weixi Huang, Jingjing Hu, Dengbin Wang, Defan Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuelin Huang *Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Zhenghai Lu *Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Huanhuan LiuDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. liuhuanhuan@xinhuamed.com.cn.
Ningxin YangDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Yanhong ChenDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Chunting WangDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Weixi HuangDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Jingjing HuDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Dengbin WangDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. wangdengbin@xinhuamed.com.cn.
Defan YaoDepartment of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. yaodefan@xinhuamed.com.cn.

Funding

Explorer Program of the Science and Technology Commission of Shanghai Municipality 24TS1415300National Natural Science Foundation of China 82472039National Natural Science Foundation of China 92159203, 82471976, 82071870Shanghai Rising-Star Program 22QA1406000
6 · The paper itself

Abstract

backgroundBreast cancer remains the most common malignancy among women worldwide. While traditional computed tomography (CT) scans and image-guided radiotherapy are widely used for breast cancer diagnosis and treatment, their efficacy is often limited. METHODS AND

resultsIn this study, we successfully synthesized human serum albumin (HSA)-based KBiF

conclusionsThis study presents a novel approach for the development of biocompatible DECT contrast agents and radiosensitizers, offering a promising strategy to enhance breast cancer diagnosis and treatment. However, the efficacy of this approach needs to be further validated across diverse breast cancer subtypes to ensure its broad applicability, which emphasizes the necessity for continued research to fully translate this innovative technology into clinical practice.

Indexed as

Breast NeoplasmsGlutathioneSerum Albumin, HumanTomography, X-Ray ComputedAnimalsCell Line, TumorContrast MediaFemaleHumansMiceMice, Inbred BALB CRadiation-Sensitizing AgentsReactive Oxygen SpeciesContrast MediaGlutathioneRadiation-Sensitizing AgentsReactive Oxygen SpeciesSerum Albumin, HumanBismuthBreast cancerContrast agentsDual-energy CTRadiotherapy

Identifiers

PMID40533758
PMCPMC12175373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.